Assessing the impact of direct-acting antivirals on hepatitis C complications: a systematic review and meta-analysis

Yew, Kuo Chao; Tan, Quan Rui; Lim, Phei Ching; Low, Wei Yang; Lee, Chong Yew

doi:10.1007/s00210-023-02716-x

Cited by 3 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 The remarkable medical breakthrough in hepatitis C treatment using direct acting agents (DAAs) has simplified the care cascades through its high efficacy in achieving sustained virological response (SVR) and tolerable side effects. 2 Indeed, DAA therapy did benefits beyond SVR, in preventing further worsening of liver status and the occurrence of cirrhosis and HCC. 2 Although DAA can cure 95% of patients, the problem lies in poor access to diagnosis and treatment in several low- and middle-income countries (LMIC).…”

Section: Introductionmentioning

confidence: 99%

“… 2 Indeed, DAA therapy did benefits beyond SVR, in preventing further worsening of liver status and the occurrence of cirrhosis and HCC. 2 Although DAA can cure 95% of patients, the problem lies in poor access to diagnosis and treatment in several low- and middle-income countries (LMIC). 1 In fact, universal DAA prescription may pose socioeconomic burdens for underprivileged LMIC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of IL-10 gene promoter polymorphisms on treatment response in HCV patients: A systematic review, a meta-analysis, and a meta-regression

Dhaouadi,

Riahi,

Ben Abdallah

et al. 2024

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

The impact of interleukin-10 (IL-10) gene promoter polymorphisms (SNPs) on treatment response in HCV patients was dissimilarly estimated. Hence, the aim of this meta-analysis was to robustly assess the effect of IL-10 SNPs on treatment response in HCV patients. An electronic literature search was carried out through PubMed, EMBASE, Web of science, and Scopus databases. Studies assessing the association between IL-10 polymorphisms and treatment response in HCV patients were included. Studies were excluded if genotype frequencies are not consistent with the Hardy–Weinberg Equilibrium (HWE) or in case of including patients with hepatitis B virus coinfection. Risk of bias in included studies was assessed using the Newcastle–Ottawa Scale. Meta-analyses were performed for the influence of IL-10 gene promoter SNPs (rs1800896 (-1082 A/G), rs1800871 (-819 C/T), and rs1800872 (-592 C/T)) and haplotypes on treatment response in HCV patients. Subgroup analyses, meta-regressions, publication bias assessment, and sensitivity analyses were also conducted. Overall, 32 studies with a total of 5943 HCV cases and 2697 controls were included in the present study. The -1082*G allele was significantly associated with increased risk of non-response (NR) to treatment, OR [95% CI] = 1.29 [1.1–1.51], p = .002. Besides, the rs1800872 -592*C allele was significantly associated with increased NR risk, OR [95% CI] = 1.22 [1.02–1.46], p = .03. Subgroup analysis showed that this association remained significant only in patients treated with PEG-IFN alone, p = .01. The -1082*G/-819*C/-592*C (GCC) haplotype was significantly associated with increased NR risk, OR [95% CI] = 1.62 [1.13–2.23], p = .009. Our results suggest that the IL-10 rs1800896 was associated with NR risk especially in North-African and Asian populations. Moreover, the IL-10 gene promoter -1082*G/-819*C/-592*C (GCC) haplotype which has been associated with higher production of IL-10, was significantly associated with increased NR risk.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact of IL-10 gene promoter polymorphisms on treatment response in HCV patients: A systematic review, a meta-analysis, and a meta-regression

Dhaouadi,

Riahi,

Ben Abdallah

et al. 2024

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan

Chang,

Hsu,

Tseng

et al. 2024

Dig Dis Sci

View full text Add to dashboard Cite

The benefits of hepatitis C viral eradication: a real-world nationwide cohort study in Taiwan

Chang,

Hsu,

Tseng

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Chronic hepatitis C (CHC) increases the risk of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). This nationwide cohort study assessed the effectiveness of viral eradication of CHC. Methods The Taiwanese chronic hepatitis C cohort and Taiwan hepatitis C virus (HCV) registry are nationwide HCV registry cohorts incorporating data from 23 and 53 hospitals in Taiwan, respectively. This study included 27,577 individuals from these cohorts that were given a diagnosis of CHC and with data linked to the Taiwan National Health Insurance Research Database. Patients received either pegylated interferon and ribavirin or direct-acting antiviral agent therapy for > 4 weeks for new-onset LC and liver-related events. Results Among the 27,577 analyzed patients, 25,461 (92.3%) achieved sustained virologic response (SVR). The mean follow-up duration was 51.2 ± 48.4 months, totaling 118,567 person-years. In the multivariable Cox proportional hazard analysis, the hazard ratio (HR) for incident HCC was 1.39 (95% confidence interval [CI]: 1.00–1.95, p = 0.052) among noncirrhotic patients without SVR compared with those with SVR, and 1.82 (95% CI: 1.34–2.48) among cirrhotic patients without SVR. The HR for liver-related events, including HCC and decompensated LC, was 1.70 (95% CI: 1.30–2.24) among cirrhotic patients without SVR. Patients with SVR had a lower 10-year cumulative incidence of new-onset HCC than those without SVR did (21.7% versus 38.7% in patients with LC, p < 0.001; 6.0% versus 18.4% in patients without LC, p < 0.001). Conclusions HCV eradication reduced the incidence of HCC in patients with and without LC and reduced the incidence of liver-related events in patients with LC.

show abstract

Assessing the impact of direct-acting antivirals on hepatitis C complications: a systematic review and meta-analysis

Cited by 3 publications

References 42 publications

Impact of IL-10 gene promoter polymorphisms on treatment response in HCV patients: A systematic review, a meta-analysis, and a meta-regression

Impact of IL-10 gene promoter polymorphisms on treatment response in HCV patients: A systematic review, a meta-analysis, and a meta-regression

Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan

The benefits of hepatitis C viral eradication: a real-world nationwide cohort study in Taiwan

Contact Info

Product

Resources

About